Zobrazeno 1 - 10
of 626
pro vyhledávání: '"KRAS G12C"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Lung cancer remains a significant health challenge, characterized by aberrant tissue growth within the pulmonary system. Early carcinogenic events often involve genomic instability and the emergence of a mutator phenotype. In this study, we
Externí odkaz:
https://doaj.org/article/0db7784893b04f35bcd86368efa78a37
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 4507-4517 (2024)
Yawan Jing,1,2 Ruixin Cheng,3 Hao Zeng,1 Qin Huang,1 Dongyu He,1 Jiayi Sun,1 Panwen Tian,1,4 Yalun Li1,4 1Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Heal
Externí odkaz:
https://doaj.org/article/61874a4feed143d3bb42c30cd01c1643
Autor:
K. K. Laktionov, K. A. Sarantseva, L. A. Nelyubina, S. V. Gamayunov, E. A. Kolesnikova, M. G. Gordiev
Publikováno v:
Сибирский онкологический журнал, Vol 23, Iss 2, Pp 72-81 (2024)
Lung cancer remains one of the most dangerous and most common cancers, requiring constant improvement of diagnostic and treatment methods. The genetic heterogeneity of lung cancer forces us to search for new therapeutic targets in an attempt to achie
Externí odkaz:
https://doaj.org/article/73b447e88d214b60aa826941c8d2573c
Autor:
Marcelo Sunagua Aruquipa, Renata D’Alpino Peixoto, Alexandre Jacome, Fernanda Cesar, Vinicius Lorandi, Rodrigo Dienstmann
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 2, Pp 1374-1382 (2024)
The association of age at the onset of CRC and the prevalence of a KRAS G12C mutation is unclear. A retrospective, multicenter study evaluating metastatic CRC patients from January 2019 to July 2023, treated at the Oncoclinicas units and tested for t
Externí odkaz:
https://doaj.org/article/1ddaaf67eb16490f9e8afdc7c434d88f
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Colorectal cancer (CRC) is a highly prevalent and lethal cancer worldwide. Approximately 45% of CRC patients harbor a gain-in-function mutation in KRAS. KRAS is the most frequently mutated oncogene accounting for approximately 25% of all human cancer
Externí odkaz:
https://doaj.org/article/b8b756094a9d42089d0c4751ec0c101a
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 14, Iss , Pp 100291- (2024)
In the last few years, non-small cell lung cancer (NSCLC) treatment has totally revolutionized by the improvement in molecular diagnostics and the introduction of targeted therapies, becoming the standard of care in patients with actionable alteratio
Externí odkaz:
https://doaj.org/article/30d1a6c3f25f4f92af1b5d2c31fefd6d
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The Kirsten rat sarcoma viral oncoprotein homolog (KRAS) is currently a primary focus of oncologists and translational scientists, driven by exciting results with KRAS-targeted therapies for non-small cell lung cancer (NSCLC) patients. While KRAS mut
Externí odkaz:
https://doaj.org/article/aca5e330a22840b09ee81bb5d601f5c2
Autor:
Katherine I. Zhou, MD, PhD, Chenyu Lin, MD, Chin-Lin Tseng, MPH, Nithya Ramnath, MBBS, Jonathan E. Dowell, MD, Michael J. Kelley, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 5, Pp 100670- (2024)
Introduction: The KRAS G12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, data on the real-world efficacy and safety of sotorasib, and to its optimal dos
Externí odkaz:
https://doaj.org/article/4f1e08331e2f48cd94d301fa4fe9842e
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Although KRAS G12C inhibitors have proven that KRAS is a “druggable” target of cancer, KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Multiple combinations of KRAS
Externí odkaz:
https://doaj.org/article/4077e8913381419588d33f240e743af9
Autor:
Pierre-Antoine Laurent, Marina Milic, Clément Quevrin, Lydia Meziani, Winchygn Liu, Daphné Morel, Nicolas Signolle, Céline Clémenson, Antonin Levy, Michele Mondini, Eric Deutsch
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-18 (2023)
Abstract Background KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was consid
Externí odkaz:
https://doaj.org/article/3cb7ef32273d492aa7ecc6fa21b1b5de